The BioCentury Show
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.
Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.
The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.
Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
Podcasting since 2024 • 43 episodes
The BioCentury Show
Latest Episodes
Ep. 92 - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future
If you could redesign FDA from the ground up, what would it look like? That’s the fundamental question underlying the 2025 BioCentury Back to School essay, authored by BioCentury Washington Editor Steve Usdin, who has been a leading voice on re...
•
Season 4
•
Episode 92
•
38:43
Ep. 91 – Annalisa Jenkins: How MHRA’s Reset Could Revive U.K. Biotech
A new head at MHRA, a streamlined government life sciences strategy, and a more sophisticated innovation ecosystem have Annalisa Jenkins optimistic about the future of U.K. biotech — and its potential to carve out a stronger global role.On ...
•
Season 4
•
Episode 91
•
36:07
Popular Episode - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
This is a previously recorded episode of The BioCentury Show from March 19, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch ...
•
Season 4
•
32:44
Ep. 90 – Inside Biopharma Dealmaking: ProFound CEO John Lepore on Knowing What Partners Want
In an environment where everybody hurts, it helps for biotech CEOs to understand the pressures driving pharmas, investors and other key players if they want to secure deals and financings that will help them succeed. That’s how John Lepore, CEO...
•
Season 4
•
Episode 90
•
33:05
Ep. 89 - Delivering on the biosimilars promise, a conversation with Gillian Woollett
Gillian Woollett, head of regulatory strategy and policy at Samsung Bioepis, discusses how FDA can deliver on its promise to “massively streamline” the regulation of biosimilars. Eliminating unnecessary clinical trial requirements could halve t...
•
Season 4
•
Episode 89
•
31:47
Contributors
.jpg)
Podcasts we love
Check out these other fine podcasts recommended by us, not an algorithm.
